Perspective Therapeutics, Inc. — Form 8-K

Perspective announced interim Phase 1/2a data for [212Pb]VMT-α-NET in SSTR2-expressing neuroendocrine tumors at ESMO 2026 (68 patients across three cohorts, data cutoff September 2, 2026). Efficacy: 33% objective response rate in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20); 72% progression-free survival at 18 months across all cohorts; disease control rates 89–95%. Safety: no dose-limiting toxicities, no Grade 4–5 adverse events, no treatment discontinuations; 29% high-grade adverse events (all Grade 3). Company targeting Phase 3 site start-up completion by year-end 2026 and Phase 3 initiation in 2027.